Aldeyra Therapeutics Inc (NASDAQ: ALDX) started the day on Wednesday, with a price increase of 4.78% at $3.51, before settling in for the price of $3.35 at the close. Taking a more long-term approach, ALDX posted a 52-week range of $1.14-$7.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 15.99%. Meanwhile, its Annual Earning per share during the time was 15.99%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 11.28%. This publicly-traded company’s shares outstanding now amounts to $60.05 million, simultaneously with a float of $58.15 million. The organization now has a market capitalization sitting at $210.23 million. At the time of writing, stock’s 50-day Moving Average stood at $2.50, while the 200-day Moving Average is $4.65.
Aldeyra Therapeutics Inc (ALDX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Aldeyra Therapeutics Inc’s current insider ownership accounts for 2.92%, in contrast to 56.16% institutional ownership. According to the most recent insider trade that took place on Apr 03 ’25, this organization’s 10% Owner sold 3,400,000 shares at the rate of 1.42, making the entire transaction reach 4,828,000 in total value, affecting insider ownership by 5,875,851. Preceding that transaction, on Aug 12 ’24, Company’s Chief Development Officer sold 16,041 for 4.74, making the whole transaction’s value amount to 75,975. This particular insider is now the holder of 236,771 in total.
Aldeyra Therapeutics Inc (ALDX) Earnings and Revenue Records
Aldeyra Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 11.28% and is forecasted to reach 0.10 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 61.78% through the next 5 years, which can be compared against the 15.99% growth it accomplished over the previous five years trading on the market.
Aldeyra Therapeutics Inc (NASDAQ: ALDX) Trading Performance Indicators
Let’s observe the current performance indicators for Aldeyra Therapeutics Inc (ALDX). It’s Quick Ratio in the last reported quarter now stands at 6.39.
In the same vein, ALDX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.97, a figure that is expected to reach -0.24 in the next quarter, and analysts are predicting that it will be 0.10 at the market close of one year from today.
Technical Analysis of Aldeyra Therapeutics Inc (ALDX)
If we take a close look at the recent performances of Aldeyra Therapeutics Inc (NASDAQ: ALDX), its last 5-days Average volume was 0.8 million that shows plunge from its year to date volume of 1.2 million. During the previous 9 days, stock’s Stochastic %D was recorded 85.06% While, its Average True Range was 0.26.
Raw Stochastic average of Aldeyra Therapeutics Inc (ALDX) in the period of the previous 100 days is set at 39.11%, which indicates a major fall in contrast to 89.39% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 70.54% that was lower than 233.51% volatility it exhibited in the past 100-days period.
